ID

27493

Beschrijving

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib; ODM derived from: https://clinicaltrials.gov/show/NCT00993499

Link

https://clinicaltrials.gov/show/NCT00993499

Trefwoorden

Versies (1)
  1. 17-11-17 17-11-17 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

17 november 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Carcinoma, Non-Small-Cell Lung NCT00993499

Engels

Eligibility Carcinoma, Non-Small-Cell Lung NCT00993499

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. pathologically or cytologically confirmed diagnosis of stage iiib or stage iv nsclc
Beschrijving

Non-Small Cell Lung Carcinoma TNM clinical staging

Datatype

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C3258246
2. patients who have failed conventional treatment (at least 1 prior treatment line), or for whom no therapy of proven efficacy exists
Beschrijving

Conventional Treatment Quantity failed | Therapeutic procedure Effective Lacking

Datatype

boolean

Alias
UMLS CUI [1,1]
C2945704
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0231175
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1280519
UMLS CUI [2,3]
C0332268
3. patients whose tumors:
Beschrijving

Malignant Neoplasms

Datatype

boolean

Alias
UMLS CUI [1]
C0006826
are egfr mutation-positive or
Beschrijving

EGFR gene mutation Positive

Datatype

boolean

Alias
UMLS CUI [1,1]
C3266992
UMLS CUI [1,2]
C1514241
are egfr mutation-negative or unknown provided they had disease progression after achieving either response or stable disease for at least 6 months from a previous treatment with erlotinib (tarceva®) or gefitinib (iressa®)
Beschrijving

EGFR gene mutation Negative | EGFR gene mutation Unknown | Disease Progression | erlotinib | Tarceva | gefitinib | Iressa | Disease Response | Stable Disease

Datatype

boolean

Alias
UMLS CUI [1,1]
C3266992
UMLS CUI [1,2]
C1513916
UMLS CUI [2,1]
C3266992
UMLS CUI [2,2]
C0439673
UMLS CUI [3]
C0242656
UMLS CUI [4]
C1135135
UMLS CUI [5]
C1135136
UMLS CUI [6]
C1122962
UMLS CUI [7]
C0919281
UMLS CUI [8]
C1704632
UMLS CUI [9]
C0677946
4. patients aged 18 years or older
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
5. life expectancy of at least three (3) months
Beschrijving

Life Expectancy

Datatype

boolean

Alias
UMLS CUI [1]
C0023671
6. eastern cooperative oncology group (ecog, r01-0787) performance score 0-2
Beschrijving

ECOG performance status

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
7. written informed consent that is consistent with ich-gcp guidelines
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. prior major surgery, chemotherapy or radiation therapy within 4 weeks before start of therapy.
Beschrijving

Major surgery | Chemotherapy | Therapeutic radiology procedure

Datatype

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C0392920
UMLS CUI [3]
C1522449
2. prior treatment with an mtor inhibitor within the past 4 weeks before start of therapy or concomitantly with this study
Beschrijving

mTOR Inhibitor

Datatype

boolean

Alias
UMLS CUI [1]
C2746052
3. use of erlotinib (tarceva®) or gefitinib (iressa®) within 14 days of run-in treatment with sirolimus
Beschrijving

erlotinib | Tarceva | gefitinib | Iressa | Sirolimus

Datatype

boolean

Alias
UMLS CUI [1]
C1135135
UMLS CUI [2]
C1135136
UMLS CUI [3]
C1122962
UMLS CUI [4]
C0919281
UMLS CUI [5]
C0072980
4. active cns metastases (defined as stable for <4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids)
Beschrijving

CNS metastases Stable | CNS metastases Symptomatic | CNS metastases Requirement Anticonvulsants | CNS metastases Requirement Steroids

Datatype

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
UMLS CUI [3,1]
C0686377
UMLS CUI [3,2]
C1514873
UMLS CUI [3,3]
C0003286
UMLS CUI [4,1]
C0686377
UMLS CUI [4,2]
C1514873
UMLS CUI [4,3]
C0038317
5. severe alteration in serum fasting cholesterol (equal or more than 350 mg/dl) or triglycerides (equal or more than 400 mg/dl). patients may be allowed to enrol on the trial after initiation of lipid lowering agents.
Beschrijving

Fasting cholesterol level Alteration Severe | Triglycerides measurement Alteration Severe | Enrollment allowed Post Initiation Hypolipidemic Agents

Datatype

boolean

Alias
UMLS CUI [1,1]
C1282513
UMLS CUI [1,2]
C1515926
UMLS CUI [1,3]
C0205082
UMLS CUI [2,1]
C0202236
UMLS CUI [2,2]
C1515926
UMLS CUI [2,3]
C0205082
UMLS CUI [3,1]
C1516879
UMLS CUI [3,2]
C0683607
UMLS CUI [3,3]
C0687676
UMLS CUI [3,4]
C1704686
UMLS CUI [3,5]
C0086440
6. requirement for treatment with any of the prohibited concomitant medications:
Beschrijving

Illicit drug use

Datatype

boolean

Alias
UMLS CUI [1]
C0281875
concomitant cyp3a4 inhibitors within the past 7 days before start of therapy or concomitantly with this study.
Beschrijving

CYP3A4 Inhibitors

Datatype

boolean

Alias
UMLS CUI [1]
C3850053
concomitant cyp3a4 inducers within the past 14 days before start of therapy or concomitantly with this study.
Beschrijving

CYP3A4 Inducers

Datatype

boolean

Alias
UMLS CUI [1]
C3850041
7. any contraindications for therapy with sirolimus.
Beschrijving

Medical contraindication Sirolimus

Datatype

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0072980
8. known hypersensitivity to bibw 2992, sirolimus or other rapamycin analogues (everolimus, temsirolimus, deforolimus, etc.) or the excipients of any of the trial drugs.
Beschrijving

Hypersensitivity BIBW 2992 | Hypersensitivity Sirolimus | Hypersensitivity Rapamycin Analogue | Hypersensitivity everolimus | Hypersensitivity temsirolimus | Hypersensitivity deforolimus | Hypersensitivity Investigational New Drugs Excipient

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C4083270
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0072980
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0072980
UMLS CUI [3,3]
C0243071
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0541315
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C1707080
UMLS CUI [6,1]
C0020517
UMLS CUI [6,2]
C2713007
UMLS CUI [7,1]
C0020517
UMLS CUI [7,2]
C0013230
UMLS CUI [7,3]
C0015237
9. use of any investigational drug within 4 weeks before start of therapy.
Beschrijving

Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1]
C0013230
Terug naar het begin van de pagina

Similar models

Eligibility Carcinoma, Non-Small-Cell Lung NCT00993499

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma TNM clinical staging
Item
1. pathologically or cytologically confirmed diagnosis of stage iiib or stage iv nsclc
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Conventional Treatment Quantity failed | Therapeutic procedure Effective Lacking
Item
2. patients who have failed conventional treatment (at least 1 prior treatment line), or for whom no therapy of proven efficacy exists
boolean
C2945704 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1280519 (UMLS CUI [2,2])
C0332268 (UMLS CUI [2,3])
Malignant Neoplasms
Item
3. patients whose tumors:
boolean
C0006826 (UMLS CUI [1])
EGFR gene mutation Positive
Item
are egfr mutation-positive or
boolean
C3266992 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
EGFR gene mutation Negative | EGFR gene mutation Unknown | Disease Progression | erlotinib | Tarceva | gefitinib | Iressa | Disease Response | Stable Disease
Item
are egfr mutation-negative or unknown provided they had disease progression after achieving either response or stable disease for at least 6 months from a previous treatment with erlotinib (tarceva®) or gefitinib (iressa®)
boolean
C3266992 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C3266992 (UMLS CUI [2,1])
C0439673 (UMLS CUI [2,2])
C0242656 (UMLS CUI [3])
C1135135 (UMLS CUI [4])
C1135136 (UMLS CUI [5])
C1122962 (UMLS CUI [6])
C0919281 (UMLS CUI [7])
C1704632 (UMLS CUI [8])
C0677946 (UMLS CUI [9])
Age
Item
4. patients aged 18 years or older
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
5. life expectancy of at least three (3) months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
6. eastern cooperative oncology group (ecog, r01-0787) performance score 0-2
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
7. written informed consent that is consistent with ich-gcp guidelines
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Major surgery | Chemotherapy | Therapeutic radiology procedure
Item
1. prior major surgery, chemotherapy or radiation therapy within 4 weeks before start of therapy.
boolean
C0679637 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
mTOR Inhibitor
Item
2. prior treatment with an mtor inhibitor within the past 4 weeks before start of therapy or concomitantly with this study
boolean
C2746052 (UMLS CUI [1])
erlotinib | Tarceva | gefitinib | Iressa | Sirolimus
Item
3. use of erlotinib (tarceva®) or gefitinib (iressa®) within 14 days of run-in treatment with sirolimus
boolean
C1135135 (UMLS CUI [1])
C1135136 (UMLS CUI [2])
C1122962 (UMLS CUI [3])
C0919281 (UMLS CUI [4])
C0072980 (UMLS CUI [5])
CNS metastases Stable | CNS metastases Symptomatic | CNS metastases Requirement Anticonvulsants | CNS metastases Requirement Steroids
Item
4. active cns metastases (defined as stable for <4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids)
boolean
C0686377 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0686377 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0003286 (UMLS CUI [3,3])
C0686377 (UMLS CUI [4,1])
C1514873 (UMLS CUI [4,2])
C0038317 (UMLS CUI [4,3])
Fasting cholesterol level Alteration Severe | Triglycerides measurement Alteration Severe | Enrollment allowed Post Initiation Hypolipidemic Agents
Item
5. severe alteration in serum fasting cholesterol (equal or more than 350 mg/dl) or triglycerides (equal or more than 400 mg/dl). patients may be allowed to enrol on the trial after initiation of lipid lowering agents.
boolean
C1282513 (UMLS CUI [1,1])
C1515926 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C0202236 (UMLS CUI [2,1])
C1515926 (UMLS CUI [2,2])
C0205082 (UMLS CUI [2,3])
C1516879 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1704686 (UMLS CUI [3,4])
C0086440 (UMLS CUI [3,5])
Illicit drug use
Item
6. requirement for treatment with any of the prohibited concomitant medications:
boolean
C0281875 (UMLS CUI [1])
CYP3A4 Inhibitors
Item
concomitant cyp3a4 inhibitors within the past 7 days before start of therapy or concomitantly with this study.
boolean
C3850053 (UMLS CUI [1])
CYP3A4 Inducers
Item
concomitant cyp3a4 inducers within the past 14 days before start of therapy or concomitantly with this study.
boolean
C3850041 (UMLS CUI [1])
Medical contraindication Sirolimus
Item
7. any contraindications for therapy with sirolimus.
boolean
C1301624 (UMLS CUI [1,1])
C0072980 (UMLS CUI [1,2])
Hypersensitivity BIBW 2992 | Hypersensitivity Sirolimus | Hypersensitivity Rapamycin Analogue | Hypersensitivity everolimus | Hypersensitivity temsirolimus | Hypersensitivity deforolimus | Hypersensitivity Investigational New Drugs Excipient
Item
8. known hypersensitivity to bibw 2992, sirolimus or other rapamycin analogues (everolimus, temsirolimus, deforolimus, etc.) or the excipients of any of the trial drugs.
boolean
C0020517 (UMLS CUI [1,1])
C4083270 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0072980 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0072980 (UMLS CUI [3,2])
C0243071 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0541315 (UMLS CUI [4,2])
C0020517 (UMLS CUI [5,1])
C1707080 (UMLS CUI [5,2])
C0020517 (UMLS CUI [6,1])
C2713007 (UMLS CUI [6,2])
C0020517 (UMLS CUI [7,1])
C0013230 (UMLS CUI [7,2])
C0015237 (UMLS CUI [7,3])
Investigational New Drugs
Item
9. use of any investigational drug within 4 weeks before start of therapy.
boolean
C0013230 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial